WHAT IS CLAIMED IS:

1. A compound or a salt thereof, wherein the compound comprises a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP) linked to a CROWN chelator by a linker, wherein:

the MC1RTP is cyclized and comprises a sequence of Formula A:

Xaa^{1}-Xaa^{2a}-Xaa^{3}-Xaa^{4}-Xaa^{5}-Xaa^{6}-Xaa^{7a} (A)

Xaa^{1} is selected from the group consisting of norleucine (Nle), D-Nle, Ala, D-Ala, Leu, D-Leu, Ile, D-Ile, Cys, D-Cys, Met, D-Met, Phe, D-Phe, Trp, D-Trp, Val, D-Val, 3-(1-naphthyl)alanine (Nal), D-Nal, 3-(2-naphthyl)alanine (2-Nal), D-2-Nal, Gly, α-aminobutyric acid, norvaline, D-norvaline, homonorleucine, and D-homonorleucine;

Xaa^{2a} is selected from the group consisting of Cys, D-Cys, Asp, D-Asp, Glu, D-Glu, 2-aminoadipic acid (2-Aad), D-2-Aad, 3-aminoadipic acid (3-Aad), D-3-Aad, propargylglycine (Pra), D-Pra, homopropargylglycine (Hpg), D-Hpg, beta-homopropargylglycine (Bpg), and D-Bpg;

Xaa^{3} is His;

Xaa^{4} is D-Phe;

Xaa^{5} is Arg;

Xaa^{6} is Trp;

Xaa^{7a} is selected from the group consisting of Cys, D-Cys, Lys, D-Lys, Orn, D-Orn, Dab, D-Dab, Dap, D-Dap, Lys(N_3), D-Lys(N_3), Orn(N_3), D-Orn(N_3), Dab(N_3), D-Dab(N_3), Dap(N_3), D-Dap(N_3), 2-(5'-azidopentyl)alanine, D-2-(5'-azidopentyl)alanine, 2-(6'-azidohexyl)alanine, and D-2-(6'-azidohexyl)alanine;

one or more amino acid residues of the MC1RTP is alpha N-methylated; and

the MC1RTP is optionally C-terminally amidated.

2. The compound of claim 1, wherein the MC1RTP is cyclized by a lactam bridge connecting Xaa^{2a} to Xaa^{7a}wherein Xaa^{2a} is Asp and Xaa^{7a} is Lys; and the lactam bridge connects the side chains of Asp and Lys.

3. The compound of claim 1 or 2, wherein Xaa^{1} is norleucine (Nle), Xaa^{2a} is Asp, Xaa^{3} is His, Xaa^{4} is D-Phe, Xaa^{5} is Arg, Xaa^{6} is Trp, and Xaa^{7a} is Lys.

4. The compound of any one of claims 1-3, wherein one or more of Xaa^{3}, Xaa^{5}, Xaa^{6}, and Xaa^{7a} is alpha N-methylated.

5. The compound of any one of claims 1-4, wherein the linker comprises an albumin binding group.

6. The compound of claim 5, wherein the linker is a linear peptide of 3 to 6 amino acid residues, –Xaa^{8}–Xaa^{9}–(Xaa^{10})$_{1-4}$–, wherein Xaa^{8}, Xaa^{9}, and Xaa^{10} are each independently an amino

acid and wherein:

the N-terminus of the MC1RTP is bonded to the free C-terminus of Xaa^{10}; and

the CROWN chelator and the albumin-binding group are bonded to the free N-terminus of Xaa^{8} and the side chain of Xaa^{9}, respectively, or


the CROWN chelator and the albumin-binding group are bonded to the side chain of Xaa^{9} and the free N-terminus of Xaa^{8}, respectively.

7. The compound of claim 6, wherein:

Xaa^{8} is Gly, Glu or D-Glu; and


Xaa^{9} is Lys or D-Lys.

8. The compound of any one of claims 1-4, wherein the linker is:



or ,

and the albumin-binding group has the following structure:



,


wherein each R^4 is independently H, halogen, C_{1-5} alkyl, C_{1-5} alkoxy, or nitro.

9. The compound of any one of claims 5-8 wherein the albumin-binding group is *N*-[4-(*p*-tolyl)butanoyl].

10. The compound of any one of claims 1-9, wherein the CROWN chelator is conjugated to a radioisotope.

11. The compound of any one of claims 1-10, wherein the CROWN chelator is conjugated to ^{213}Bi, ^{177}Lu, ^{225}Ac, ^{149}Tb, ^{152}Tb, ^{155}Tb, ^{161}Tb, or ^{227}Th.

12. A compound having the structure:



, or a salt thereof.

13. The compound of claim 12, conjugated to ^{213}Bi, ^{177}Lu, ^{225}Ac, ^{149}Tb, ^{152}Tb, ^{155}Tb, ^{161}Tb, or ^{227}Th.

14. Use of the compound of any one of claims 1-13 for the manufacture of a medicament for treating melanoma.

15. The use of claim 14, wherein the melanoma is metastatic cutaneous melanoma or metastatic uveal melanoma.